|
Online Database of Chemicals from Around the World | 产品搜索 | 产品提交 | 产品推广 | |
网站主页 >> 化工产品目录 >> 胰淀素>> 市场分析报告 |
胰淀素市场分析报告 |
|
Amylin Pharmaceuticals, Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis Amylin Pharmaceuticals, Inc., a biopharmaceutical company, engages in ... Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Pipeline Review, H2 2018 ... involved in Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or ... involved in Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or ... understanding Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma ... Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Pipeline Review, H1 2018 ... involved in Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or ... involved in Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or ... understanding Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma ... Global Market Report of AMYLIN (1-13) (HUMAN) (CAS 198328-30-2) December 2024 Global Market Report of AMYLIN (8-37) (RAT) (CAS 138398-61-5) December 2024 Global Market Report of AMYLIN (8-37) (HUMAN) (CAS 135702-23-7) December 2024 Global Market Report of AMYLIN, HUMAN (CAS 122384-88-7) December 2024 Amylin Pharmaceuticals, Inc. - Business Profile with Financial and SWOT Analysis Amylin Pharmaceuticals, Inc. - Business Profile with Financial and SWOT Analysis provides access to trustworthy data on the company and its performance, presenting an all-around view. It offers an insightful overview of the company’s structure and recent operations, includes SWOT analysis, highlights product and service offerings, covers the latest important corporate actions and financial results. Diabetes Drug Market, Oral (DPP IV Inhibitor, SGLT-2, Alpha Glucosidase Inhibitor, Biguanide) Injection (Glucagon-like peptide (GLP) 1 agonist, Amylin Receptor Agonist), Insulin (Rapid – Acting Insulin, Long Acting Insulin, Premixed Insulin), Regions (United States, Europe, Japan, China, India, Brazil), Companies (Novo Nordisk, Merck & Co, Eli Lilly, AstraZeneca, Johnson & Johnson, Boehringer Ingelheim) ... Glucagon-like peptide (GLP) 1 agonist, Amylin Receptor Agonist), Insulin (Rapid – Acting ... like peptide (GLP) 1 agonist and Amylin receptor agonist market. Insulin ... Glucagon-like peptide (GLP) 1 agonist 2. Amylin receptor agonist Insulin 1. Rapid – Acting ... Islet Amyloid Polypeptide - Pipeline Review, H2 2020 ... muscle. Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or ... involved in Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or ... understanding Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma ... Islet Amyloid Polypeptide - Pipeline Review, H1 2020 ... involved in Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or ... involved in Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or ... understanding Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma ... Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Drugs in Development, 2021 ... involved in Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or ... involved in Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or ... understanding Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma ... Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update ... involved in Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or ... involved in Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or ... understanding Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma ... Alexandria Real Estate Equities Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis ... of Technology, Theravance, Inc., Genentech, Inc., Amylin Pharmaceuticals, Inc., Amgen, Inc., and ... Alkermes, Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis ... The company is collaborating with Amylin Pharmaceuticals, Inc. (Amylin) on the development of a once weekly ... of type 2 diabetes. BYDUREON is an injectable formulation of Amylins BYETTA (exenatide) and is being developed ... Eli Lilly & Co. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis ... . The company co-promotes Byetta with Amylin Pharmaceuticals, Inc. in the United States ... Orexigen Therapeutics, Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis ... , Inc., GlaxoSmithKline, Arena Pharmaceuticals, Inc., Amylin Pharmaceuticals, Inc., Alizyme plc, Athersys ... Takeda Pharmaceutical Co. Ltd. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis ... differs from antidepressants. In November 2009, Amylin Pharmaceuticals Inc. and Takeda Pharmaceutical ... agreement includes products to be developed from Amylin's pipeline, including pramlintide/metreleptin and ... Turn of The Decade: Novel Glp-1’s To Emerge as the New Leader in Diabetes Class ... current marketed GLP-1’s. Besides Lilly, Amylin and Novo Nordisk, Hanmi Pharmaceuticals ... Diabetes - KOL Insight and Consensus Outlook Modules ... GSK’s Eperzan (albiglutide) and BMS/AZ/Amylin’s Bydureon (exanatide) but meaningful ... exenatide; Bristol-Myers Squibb/AstraZeneca/Amylin) forecast Bydureon (exenatide once- ... ; Bristol-Myers Squibb/AstraZeneca/ Amylin) forecast Victoza (liraglutide; Novo ... |